Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis
- 17 November 2006
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 350 (2), 352-357
- https://doi.org/10.1016/j.bbrc.2006.09.049
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Novel modulators of poly(ADP-ribose) polymeraseTrends in Pharmacological Sciences, 2006
- Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrationsProceedings of the National Academy of Sciences, 2006
- Characterization of dendrimersAdvanced Drug Delivery Reviews, 2005
- Role of Poly(ADP-Ribose) Polymerase-1 Activation in the Pathogenesis of Diabetic Complications: Endothelial Dysfunction, as a Common Underlying ThemeAntioxidants and Redox Signaling, 2005
- PARP-1 inhibition to treat cancer, ischemia, inflammationPharmacological Research, 2005
- Nitrosative stress and pharmacological modulation of heart failureTrends in Pharmacological Sciences, 2005
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient CellsClinical Cancer Research, 2004
- Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cellsCell Death & Differentiation, 2001